Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.0
7.8
Journals
Vaccines
Special Issues
Rabies Vaccination and Immunotherapy
share announcement

Rabies Vaccination and Immunotherapy

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Vaccines against Infectious Diseases".

Deadline for manuscript submissions: closed (20 August 2022) | Viewed by 4184

Special Issue Editor

Dr. April D. Davis

E-Mail Website
Guest Editor
The Laboratory of Immunology, The Wadsworth Center, New York State Department of Health, Albany, NY 12201-2002, USA
Interests: rabies virus; immunopathology; immune evasion; vaccines; antibodies; antivirals
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Although rabies virus is nearly 100% fatal once clinical signs develop, it is also a vaccine-preventable disease. However, multiple factors have impeded successful and widespread administration of rabies vaccines and immunotherapies, including expense and the need for cold chain storage in areas that are remote and may lack reliable electricity. Additionally, vaccines and immunotherapies for rabies virus need to demonstrate high efficacy given the potential for a fatal outcome in untreated or inadequately treated individuals exposed to rabies virus.

The goal of this Special Issue is to feature manuscripts addressing the advancements in the treatment and prevention of rabies infection, including but not limited to developing effective rabies vaccines, novel therapeutics, antiviral response, animal models, and delivery methods. Research articles that describe prevention and potential treatment for lyssavirus phylogroups II and III are also welcome.

Dr. April D. Davis
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Rabies
  • Vaccine
  • Antibodies
  • Post-exposure prophylaxis
  • Host response
  • Animal model

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

14 pages, 2532 KiB  
Article
Comparable Long-Term Rabies Immunity in Foxes after IntraMuscular and Oral Application Using a Third-Generation Oral Rabies Virus Vaccine
by Verena te Kamp, Virginia Friedrichs, Conrad M. Freuling, Ad Vos, Madlin Potratz, Antonia Klein, Luca M. Zaeck, Elisa Eggerbauer, Peter Schuster, Christian Kaiser, Steffen Ortmann, Antje Kretzschmar, Katharina Bobe, Michael R. Knittler, Anca Dorhoi, Stefan Finke and Thomas Müller
Vaccines 2021, 9(1), 49; https://doi.org/10.3390/vaccines9010049 - 14 Jan 2021
Cited by 4 | Viewed by 3206
Abstract
The live genetically-engineered oral rabies virus (RABV) variant SPBN GASGAS induces long-lasting immunity in foxes and protection against challenge with an otherwise lethal dose of RABV field strains both after experimental oral and parenteral routes of administration. Induction of RABV-specific binding antibodies and [...] Read more.
The live genetically-engineered oral rabies virus (RABV) variant SPBN GASGAS induces long-lasting immunity in foxes and protection against challenge with an otherwise lethal dose of RABV field strains both after experimental oral and parenteral routes of administration. Induction of RABV-specific binding antibodies and immunoglobulin isotypes (IgM, total IgG, IgG1, IgG2) were comparable in orally and parenterally vaccinated foxes. Differences were only observed in the induction of virus-neutralizing (VNA) titers, which were significantly higher in the parenterally vaccinated group. The dynamics of rabies-specific antibodies pre- and post-challenge (365 days post vaccination) suggest the predominance of type-1 immunity protection of SPBN GASGAS. Independent of the route of administration, in the absence of IgG1 the immune response to SPBN GAGAS was mainly IgG2 driven. Interestingly, vaccination with SPBN GASGAS does not cause significant differences in inducible IFN-γ production in vaccinated animals, indicating a relatively weak cellular immune response during challenge. Notably, the parenteral application of SPBN GASGAS did not induce any adverse side effects in foxes, thus supporting safety studies of this oral rabies vaccine in various species. Full article
(This article belongs to the Special Issue Rabies Vaccination and Immunotherapy)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop